BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Granules India Ltd. delivered better-than-expected Q4 FY22 performance at operational level.
Better realisation from paracetamol supported by new launches resulted in improved profitability on a QoQ basis.
We are optimistic about Granules India as we expect multiple levers such as:
reducing impact of paracetamol’s raw material prices,
healthy launches in developed markets such as the U.S./Europe,
steady market share gain in core molecules across global markets and
improving business prospects from multiple unit pellet system/ Oncology blocks, to play out over the next two-three years.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.